Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 432

1.

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy.

Castoldi F, Vacchelli E, Zitvogel L, Maiuri MC, Pietrocola F, Kroemer G.

Oncoimmunology. 2018 Oct 1;8(1):e1498285. doi: 10.1080/2162402X.2018.1498285. eCollection 2019.

2.

Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Oct 11;7(12):e1526250. doi: 10.1080/2162402X.2018.1526250. eCollection 2018. Review.

PMID:
30524908
3.

Trial watch: Peptide-based vaccines in anticancer therapy.

Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Sep 6;7(12):e1511506. doi: 10.1080/2162402X.2018.1511506. eCollection 2018. Review.

4.

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

G Pol J, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, R Clements D, Fahrner JE, Fend L, C Bell J, L Mossman K, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018. Review.

PMID:
30524901
5.

CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes.

Frazao A, Messaoudene M, Nunez N, Dulphy N, Roussin F, Sedlik C, Zitvogel L, Piaggio E, Toubert A, Caignard A.

Cancer Immunol Res. 2018 Dec 4. doi: 10.1158/2326-6066.CIR-18-0085. [Epub ahead of print]

PMID:
30514793
6.

Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers.

Jacquelot N, Duong CPM, Belz GT, Zitvogel L.

Front Immunol. 2018 Oct 29;9:2480. doi: 10.3389/fimmu.2018.02480. eCollection 2018. Review.

7.

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.

Hirsch L, Zitvogel L, Eggermont A, Marabelle A.

Br J Cancer. 2019 Jan;120(1):3-5. doi: 10.1038/s41416-018-0294-4. Epub 2018 Nov 9.

PMID:
30413824
8.

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.

De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M.

Cytokine Growth Factor Rev. 2018 Dec;44:1-10. doi: 10.1016/j.cytogfr.2018.10.005. Epub 2018 Oct 30.

PMID:
30393044
9.

Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals.

Zhou H, Mondragón L, Xie W, Mauseth B, Leduc M, Sauvat A, Gomes-da-Silva LC, Forveille S, Iribarren K, Souquere S, Bezu L, Liu P, Zhao L, Zitvogel L, Sveinbjørnsson B, Eksteen JJ, Rekdal Ø, Kepp O, Kroemer G.

Cell Death Dis. 2018 Oct 23;9(11):1086. doi: 10.1038/s41419-018-1127-3.

10.

The intimate relationship between gut microbiota and cancer immunotherapy.

Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B.

Gut Microbes. 2018 Oct 19:1-5. doi: 10.1080/19490976.2018.1527167. [Epub ahead of print]

PMID:
30339501
11.

Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts.

Stoll G, Pol J, Soumelis V, Zitvogel L, Kroemer G.

Oncoimmunology. 2018 Aug 6;7(10):e1484980. doi: 10.1080/2162402X.2018.1484980. eCollection 2018.

12.

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves.

Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G.

Oncoimmunology. 2018 Aug 1;7(9):e1462431. doi: 10.1080/2162402X.2018.1462431. eCollection 2018.

13.

Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'.

Jacquelot N, Zitvogel L, Eggermont AM.

Nat Commun. 2018 Jul 26;9(1):2922. doi: 10.1038/s41467-018-05048-0. No abstract available.

14.

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1.

Derosa L, Routy B, Kroemer G, Zitvogel L.

Oncoimmunology. 2018 Apr 18;7(6):e1434468. doi: 10.1080/2162402X.2018.1434468. eCollection 2018.

PMID:
29872574
15.

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Feb 15;7(6):e1433982. doi: 10.1080/2162402X.2018.1433982. eCollection 2018. Review.

PMID:
29872569
16.

The gut microbiota influences anticancer immunosurveillance and general health.

Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G.

Nat Rev Clin Oncol. 2018 Jun;15(6):382-396. doi: 10.1038/s41571-018-0006-2. Review.

PMID:
29636538
17.

The impact of the intestinal microbiota in therapeutic responses against cancer.

Goubet AG, Daillère R, Routy B, Derosa L, M Roberti P, Zitvogel L.

C R Biol. 2018 May - Jun;341(5):284-289. doi: 10.1016/j.crvi.2018.03.004. Epub 2018 Apr 7. Review.

18.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.

PMID:
29617710
19.

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.

Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF.

Science. 2018 Mar 23;359(6382):1366-1370. doi: 10.1126/science.aar6918. Review.

PMID:
29567708
20.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.

Immunity. 2018 Feb 20;48(2):396-398. doi: 10.1016/j.immuni.2018.01.010. No abstract available.

21.

Cancer immunotherapy in 2017: The breakthrough of the microbiota.

Kroemer G, Zitvogel L.

Nat Rev Immunol. 2018 Jan 30;18(2):87-88. doi: 10.1038/nri.2018.4. No abstract available.

PMID:
29379189
22.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

23.

eIF2α phosphorylation is pathognomonic for immunogenic cell death.

Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S, Garcia P, Zhao L, Liu P, Zitvogel L, Senovilla L, Kepp O, Kroemer G.

Cell Death Differ. 2018 Aug;25(8):1375-1393. doi: 10.1038/s41418-017-0044-9. Epub 2018 Jan 22.

PMID:
29358668
24.

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.

Immunity. 2018 Jan 16;48(1):107-119.e4. doi: 10.1016/j.immuni.2017.12.007. Epub 2018 Jan 9. Erratum in: Immunity. 2018 Feb 20;48(2):396-398.

PMID:
29329948
25.

Immunogenic and Non-immunogenic Cell Death in the Tumor Microenvironment.

Pitt JM, Kroemer G, Zitvogel L.

Adv Exp Med Biol. 2017;1036:65-79. doi: 10.1007/978-3-319-67577-0_5. Review.

PMID:
29275465
26.

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.

Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ.

Cancer Res. 2018 Feb 15;78(4):1003-1016. doi: 10.1158/0008-5472.CAN-17-2826. Epub 2017 Dec 11.

PMID:
29229601
27.

Trial watch: DNA-based vaccines for oncological indications.

Pierini S, Perales-Linares R, Uribe-Herranz M, Pol JG, Zitvogel L, Kroemer G, Facciabene A, Galluzzi L.

Oncoimmunology. 2017 Nov 20;6(12):e1398878. doi: 10.1080/2162402X.2017.1398878. eCollection 2017. Review.

28.

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2017 Oct 4;6(12):e1386829. doi: 10.1080/2162402X.2017.1386829. eCollection 2017. Review.

29.

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L.

Oncoimmunology. 2017 Aug 30;6(12):e1371896. doi: 10.1080/2162402X.2017.1371896. eCollection 2017. Review.

30.

Trial watch: Immune checkpoint blockers for cancer therapy.

Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2017 Aug 31;6(11):e1373237. doi: 10.1080/2162402X.2017.1373237. eCollection 2017. Review.

31.

Trial Watch: Adoptively transferred cells for anticancer immunotherapy.

Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L.

Oncoimmunology. 2017 Aug 11;6(11):e1363139. doi: 10.1080/2162402X.2017.1363139. eCollection 2017. Review.

32.

The oncolytic compound LTX-401 targets the Golgi apparatus.

Zhou H, Sauvat A, Gomes-da-Silva LC, Durand S, Forveille S, Iribarren K, Yamazaki T, Souquere S, Bezu L, Müller K, Leduc M, Liu P, Zhao L, Marabelle A, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G.

Cell Death Differ. 2018 Jan;25(1):227-228. doi: 10.1038/cdd.2017.148. Epub 2017 Nov 10.

33.

Identification of pharmacological agents that induce HMGB1 release.

Liu P, Zhao L, Loos F, Iribarren K, Lachkar S, Zhou H, Gomes-da-Silva LC, Chen G, Bezu L, Boncompain G, Perez F, Zitvogel L, Kepp O, Kroemer G.

Sci Rep. 2017 Nov 2;7(1):14915. doi: 10.1038/s41598-017-14848-1.

34.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
35.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

36.

Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance.

Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buqué A, Humeau J, Drijfhout JW, Meurice G, Walter S, Fritsche J, Weinschenk T, Rammensee HG, Melief C, Thibault P, Perreault C, Pol J, Zitvogel L, Senovilla L, Kroemer G.

Immunol Rev. 2017 Nov;280(1):165-174. doi: 10.1111/imr.12582. Review.

PMID:
29027230
37.

TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.

Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L.

Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018.

38.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

39.

Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Jacquelot N, Pitt JM, Enot DP, Roberti MP, Duong CPM, Rusakiewicz S, Eggermont AM, Zitvogel L.

Oncoimmunology. 2017 Mar 7;6(8):e1299303. doi: 10.1080/2162402X.2017.1299303. eCollection 2017. Review.

40.

Trial watch: Dendritic cell-based anticancer immunotherapy.

Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2017 May 12;6(7):e1328341. doi: 10.1080/2162402X.2017.1328341. eCollection 2017. Review.

41.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ.

Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31.

PMID:
28759001
42.

The immune contexture in cancer prognosis and treatment.

Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G.

Nat Rev Clin Oncol. 2017 Dec;14(12):717-734. doi: 10.1038/nrclinonc.2017.101. Epub 2017 Jul 25. Review.

PMID:
28741618
43.

Nutrition, inflammation and cancer.

Zitvogel L, Pietrocola F, Kroemer G.

Nat Immunol. 2017 Jul 19;18(8):843-850. doi: 10.1038/ni.3754. Review.

PMID:
28722707
44.

[Gut microbiota and efficacy of cancer therapies].

Vétizou M, Daillère R, Zitvogel L.

Biol Aujourdhui. 2017;211(1):51-67. doi: 10.1051/jbio/2017009. Epub 2017 Jul 6. Review. French.

PMID:
28682227
45.

Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.

Frazao A, Colombo M, Fourmentraux-Neves E, Messaoudene M, Rusakiewicz S, Zitvogel L, Vivier E, Vély F, Faure F, Dréno B, Benlalam H, Bouquet F, Savina A, Pasmant E, Toubert A, Avril MF, Caignard A.

Cancer Immunol Res. 2017 Jul;5(7):582-593. doi: 10.1158/2326-6066.CIR-16-0380. Epub 2017 Jun 2.

46.

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, Préville X, Quéméneur E, Kepp O, Adam J, Marabelle A, Pitt JM, Kroemer G, Zitvogel L.

Cancer Res. 2017 Aug 1;77(15):4146-4157. doi: 10.1158/0008-5472.CAN-16-2165. Epub 2017 May 23.

47.

Anticancer effects of the microbiome and its products.

Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G.

Nat Rev Microbiol. 2017 Aug;15(8):465-478. doi: 10.1038/nrmicro.2017.44. Epub 2017 May 22. Review.

PMID:
28529325
48.

Pro-necrotic molecules impact local immunosurveillance in human breast cancer.

Stoll G, Ma Y, Yang H, Kepp O, Zitvogel L, Kroemer G.

Oncoimmunology. 2017 Apr 17;6(4):e1299302. doi: 10.1080/2162402X.2017.1299302. eCollection 2017.

49.

Reply: Immunosuppressive cell death in cancer.

Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G.

Nat Rev Immunol. 2017 Jun;17(6):402. doi: 10.1038/nri.2017.48. Epub 2017 May 8. No abstract available.

PMID:
28480896
50.

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, Kroemer G, Zitvogel L.

Oncoimmunology. 2016 May 13;6(1):e1163456. doi: 10.1080/2162402X.2016.1163456. eCollection 2017.

Supplemental Content

Loading ...
Support Center